共 69 条
- [1] Colao A(2003)Gender differences in the prevalence, clinical features and response to cabergoline in hyperprolactinemia Eur J Endocrinol 148 325-331
- [2] Sarno AD(2006)Advances in the treatment of prolactinomas Endocr Rev 27 485-534
- [3] Cappabianca P(2014)Therapy of endocrine disease: the challenges in managing giant prolactinomas Eur. J. Endocrinol. 170 R 213-227
- [4] Briganti F(2002)Giant prolactinomas: clinical management and long-term follow up J Neurosurg 97 299-306
- [5] Pivonello R(2003)Giant prolactinomas in men: efficacy of cabergoline treatment Clin Endocrinol (Oxf) 58 662-670
- [6] Somma CD(2007)Effectiveness of long-term cabergoline treatment for giant prolactinomas: study of 12 men Eur J Endocrinol 156 225-231
- [7] Faggiano A(2013)Giant prolactinomas in women Eur J Endocrinol 170 31-38
- [8] Biondi B(2011)Unusual clinical presentations of giant prolactinomas Pituitary 14 340-344
- [9] Lombardi G(1992)Treatment of extensively invasive (giant) prolactinomas with bromocriptine N Z Med J 105 129-131
- [10] Gillman MP(2004)Outcome of cabergoline treatment in men with prolactinoma: effects of a 24-month treatment on prolactin levels, tumor mass, recovery of pituitary function, and semen analysis J Clin Endocrinol Metab 89 1704-1711